Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

@article{Smith2012InterimA,
  title={Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).},
  author={Matthew Raymond Smith and Johann S de Bono and Arturo Molina and Christopher J. Logothetis and Paul L de Souza and Karim S Fizazi and Paul N. Mainwaring and Jose Maria Piulats Rodriguez and Siobhan S Ng and Joan Carles and Peter F. A. Mulders and Thian San Kheoh and Thomas W. Griffin and Eric Jay Small and Howard I. Scher and Dana E. Rathkopf},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 18_suppl},
  pages={LBA4518}
}
LBA4518 Background: AA is an androgen biosynthesis inhibitor that inhibits CYP17 and improves overall survival (OS) in post-docetaxel mCRPC. The primary objective of COU-AA-302 was to compare clinical benefit of AA + prednisone (P) vs placebo (PL) + P in chemo-naive, asymptomatic/mildly symptomatic mCRPC pts. METHODS 1088 pts (151 centers; 12 countries) were randomized 1:1 to AA (1 g) + P (5 mg BID) or PL + P. Co-primary endpoints: radiographic progression-free survival (rPFS) and OS. Median… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…